📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-11 00:39
477 analysed today
FollowTelegram
477
Today
149,878
All-time analysed
42,959
Positive
6,669
Negative
91,543
Neutral
8,639
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
30% Revenue Growth in Q1 FY27; Oncology Segment Leads with ₹464.9 Cr Revenue
AstraZeneca India reported a strong start to FY2026-27 with total revenue from operations reaching ₹682.8 Cr, a 30% increase YoY. The Oncology segment remains the primary driver, contributing approximately 68% of total revenue at ₹464.9 Cr. Profit before tax for the quarter stood at ₹50.7 Cr. The company secured three key regulatory approvals in Oncology (Acalabrutinib and Trastuzumab deruxtecan) and saw its Rare Disease segment grow 35x from a small base.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, showing a significant revenue acceleration and the receipt of three new regulatory approvals for key oncology treatments.
Why it mattersThe 30% revenue growth validates the company's strategy to offset patent expiries with new innovative launches; the high concentration in Oncology (68% of revenue) aligns with high-growth therapy areas.
Q1 Revenue: ₹682.8 CrRevenue Growth (YoY): 30%Oncology Revenue: ₹464.9 CrProfit Before Tax: ₹50.7 CrQ1 Revenue vs TTM Revenue: 35.3%
📅 Short termThe stock may react positively to the strong top-line growth and regulatory milestones, though the high P/E ratio (175.8) may limit immediate upside.
📈 Long termThe structural shift towards a high-margin, innovation-driven portfolio (Oncology and Rare Diseases) is positive, though the transition to an import-based model increases dependency on the parent entity.
⚠ Risk flags
- High dependency on parent entities for product supply
- Ongoing exit from Bangalore manufacturing site
- High valuation with a P/E of 175.8
Key Highlights
Total revenue from operations grew 30% YoY to ₹682.8 Cr in Q1 FY27
Oncology segment revenue reached ₹464.9 Cr, representing 26% growth
Rare Disease segment saw a 35x growth, contributing ₹14.4 Cr to the top line
Received 3 major regulatory approvals for Acalabrutinib and Trastuzumab deruxtecan in Oncology
Signed MoU with Telangana Government for AI-enabled lung cancer screening across 20 facilities
👀 What to Watch
Monitor the commercial ramp-up of the newly approved Oncology drugs and the impact of the Bangalore manufacturing site exit on operating margins in upcoming quarters.
₹36 Dividend Approved at 47th AGM; New Statutory Auditors Appointed
AstraZeneca Pharma India Limited concluded its 47th Annual General Meeting on August 10, 2026, where shareholders approved a dividend of ₹36 per equity share. The meeting also finalized the appointment of M/s. BSR & Co. LLP as statutory auditors and the re-appointment of Ms. Shilpa Divekar Nirula as an Independent Director for a five-year term. The dividend payout is significant relative to the TTM EPS of ₹46.02, representing a payout ratio of approximately 78%. The company continues its strategic transition toward an import-based specialist model while exiting its Bangalore manufacturing facility.
Confidence: HIGH
What changedShareholders have formally ratified the FY26 financial results, the dividend payout, and key leadership/auditor appointments.
Why it mattersThe approval ensures governance continuity and confirms the cash return to shareholders, which is notable given the company's high P/E valuation of 175.8 and its shift toward a trading-heavy business model.
Dividend per share: ₹36Dividend vs TTM EPS: ~78.2%Independent Director Term: 5 yearsTTM Revenue: ₹1933 CrMarket Cap: ₹20227 Cr
📅 Short termThe stock price is likely to remain stable as the AGM proceedings were procedural and the dividend was expected. The dividend yield is modest at approximately 0.44% based on the current price.
📈 Long termLimited structural impact from this filing; the long-term outlook depends on the successful launch of innovative medicines from the parent pipeline and managing the margin impact of the manufacturing exit.
⚠ Risk flags
- High dependency on parent entities for product supply
- Margin pressure from shift to trading-heavy product mix
- Patent expiry of key drugs impacting revenue
Key Highlights
Dividend of ₹36 per equity share declared for the financial year ended March 31, 2026.
Appointment of M/s. BSR & Co. LLP as Statutory Auditors of the Company.
Re-appointment of Ms. Shilpa Divekar Nirula as Independent Director for a 5-year term (2026-2031).
Adoption of Financial Statements for FY26 and the Reports of the Board and Auditors.
AGM conducted via Video Conferencing, concluding at 5:20 P.M. after a 18-minute delay for quorum.
👀 What to Watch
Investors should monitor the official voting results and the specific record date for the dividend disbursement. The strategic exit from the Bangalore manufacturing site remains the primary operational shift to track for long-term margin impact.
30% Revenue Growth in Q1 FY27; AstraZeneca India Reports Rs 682.8 Cr Revenue
AstraZeneca Pharma India reported a strong start to FY27 with revenue from operations growing 30% YoY to Rs 682.8 Cr. Profit after tax (PAT) for the quarter ended June 30, 2026, stood at Rs 50.7 Cr. Growth was primarily driven by the Oncology segment, which grew 26% to Rs 464.9 Cr, and a massive 35x surge in the Rare Disease segment to Rs 14.4 Cr. The company also announced the appointment of Mr. Arun Krishna as an Additional Director and the transition of CFO Bhavana Agrawal to a Non-Executive role.
Confidence: HIGH
What changedAstraZeneca India reported its Q1 FY27 financial results showing 30% top-line growth and announced the appointment of a new Additional Director alongside a CFO transition.
Why it mattersThe results validate the company's strategic shift toward high-value therapy areas like Oncology and Rare Diseases, which are growing faster than the broader portfolio. The 30% revenue growth is significant compared to the TTM revenue of Rs 1,933 Cr.
Q1 Revenue: Rs 682.8 CrQ1 Revenue vs TTM Revenue: 35.3%Oncology Growth: 26%Rare Disease Growth: 35xQ1 PAT: Rs 50.7 Cr
📅 Short termThe strong 30% revenue growth and segment-specific performance are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe company is successfully transitioning to an innovation-led, import-based specialist model focusing on high-margin chronic therapies, though high parent dependency remains a structural feature.
⚠ Risk flags
- High dependency on parent entities for product supply
- High valuation (P/E 178.7)
- Ongoing exit from Bangalore manufacturing facility
Key Highlights
Total revenue from operations increased 30% YoY to Rs 682.8 Cr in Q1 FY27.
Oncology segment revenue reached Rs 464.9 Cr, contributing approximately 68% of total revenue.
Rare Disease segment revenue grew 35x compared to Q1 FY26, reaching Rs 14.4 Cr.
Received three key regulatory approvals for Acalabrutinib and Trastuzumab deruxtecan during the quarter.
Profit after tax (PAT) for the quarter was reported at Rs 50.7 Cr.
👀 What to Watch
Investors should monitor the commercial ramp-up of the three newly approved drugs and the impact of the Bangalore manufacturing site exit on long-term margins. The high P/E of 178.7 suggests the market has priced in significant growth, making consistent execution in Oncology and Rare Diseases critical.
AstraZeneca India Receives CDSCO Approval for Enhertu in Additional Breast Cancer Indication
AstraZeneca Pharma India has received permission from the CDSCO to import and market Enhertu (Trastuzumab Deruxtecan 100mg/5mL) for an additional indication. The approval covers the adjuvant treatment of adult patients with HER2-positive breast cancer who have residual invasive disease following neoadjuvant therapy. This expansion strengthens the company's oncology portfolio, which is a key growth driver; for context, its oncology drug Tagrisso recorded sales of Rs 319.9 Cr in FY24. The move aligns with the company's strategy to bring innovative medicines to India to offset revenue impacts from patent expiries like Lynparza.
Confidence: HIGH
What changedAstraZeneca has gained regulatory clearance to market its existing drug Enhertu for a specific additional stage of breast cancer treatment in India.
Why it mattersExpanding indications for high-value innovative drugs is crucial for MNC pharma companies to maximize the lifecycle value of their patents and maintain growth in the competitive oncology market.
Product Strength: 100mg/5mLTagrisso FY24 Sales: Rs 319.9 CrTTM Revenue: Rs 1933 CrPromoter Holding: 75.0%
📅 Short termThe news is likely to be viewed positively by the market as it demonstrates a continuous pipeline of regulatory approvals for high-margin products.
📈 Long termThis supports the company's structural shift toward a high-margin, innovation-led trading model, though it remains dependent on the parent's global pipeline and supply chain.
⚠ Risk flags
- High dependency on parent entities for product supply
- Patent expiry risks for other key drugs
- Gross margin pressure from trading-heavy product mix
Key Highlights
Received CDSCO permission on August 7, 2026, for import and sale of Enhertu 100mg/5mL.
New indication targets HER2-positive (IHC 3+ or ISH+) breast cancer patients with residual disease.
Oncology remains a core segment, with Tagrisso contributing Rs 319.9 Cr to FY24 revenue.
Company is targeting a 30% expected growth rate through such innovative medicine launches.
Strategic shift continues toward an import-based specialist model following the planned exit from the Bangalore manufacturing site.
👀 What to Watch
Investors should monitor the oncology segment's revenue contribution in upcoming quarters to gauge the commercial uptake of this new indication.
Rs 148.66 Cr NPPA Demand Notice for Alleged Overcharging on Symbicort Inhaler
AstraZeneca Pharma India has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for Rs 148.66 Cr, including interest. The notice alleges overcharging for the Symbicort Turbuhaler 160/4.5 (Inhaler) over a nearly 10-year period from May 2016 to November 2025. This demand is highly material as it represents approximately 129% of the company's TTM Net Profit (Rs 115 Cr) and 17% of its Net Worth (Rs 873 Cr). The company is currently evaluating legal actions to contest the demand.
Confidence: HIGH
What changedA regulatory show-cause notice from September 2025 has escalated into a formal demand for payment of Rs 148.66 Cr by the NPPA.
Why it mattersThe financial magnitude is significant, representing more than a full year's profit, which could severely impact cash reserves and dividend potential if the company is unsuccessful in its legal challenge.
Demand Amount: Rs 1,48,65,83,590Demand vs TTM PAT: ~129%Demand vs Net Worth: ~17%Interest calculated upto: August 20, 2026Overcharge Period: May 2016 to November 2025
📅 Short termThe stock is likely to face downward pressure as the demand amount is substantial relative to annual earnings and net worth.
📈 Long termThis highlights the ongoing regulatory risk for MNC pharma companies under the DPCO framework in India; litigation could span several years.
⚠ Risk flags
- Regulatory penalty
- Significant impact on PAT
- Litigation risk
- Cash flow impact
Key Highlights
Demand notice of Rs 1,48,65,83,590 (Rs 148.66 Cr) issued by NPPA for alleged overcharging.
Alleged overcharging period covers May 2016 to November 2025 for Symbicort Turbuhaler 160/4.5.
The demand includes interest calculated up to August 20, 2026, and is payable within 30 days.
The notice follows a previous show-cause notice issued on September 11, 2025.
The demand amount of Rs 148.66 Cr exceeds the company's TTM PAT of Rs 115 Cr.
👀 What to Watch
Monitor whether the company obtains a legal stay on the demand or if it chooses to provide for this liability in the upcoming quarterly results. Watch for any further disclosures regarding the Department of Pharmaceuticals' review process.
AstraZeneca India Receives CDSCO Approval for Enhertu® Additional Indication
AstraZeneca Pharma India has received permission from the CDSCO to import and market Enhertu® (Trastuzumab Deruxtecan 100mg/5mL) for an additional indication. The drug is now approved for the neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer. This expansion aligns with the company's 'Growth through Innovation' strategy, targeting high-growth segments like Oncology. While specific revenue impact for this indication is not disclosed, Oncology remains a critical driver, with products like Tagrisso contributing Rs 319.9 Cr in FY24.
Confidence: HIGH
What changedAstraZeneca has gained regulatory clearance to market its key oncology drug, Enhertu®, for early-stage (Stage II and III) HER2-positive breast cancer in India.
Why it mattersExpanding indications for innovative drugs is vital for ASTRAZEN to maintain its high growth rate (30% expected) and offset revenue losses from patent expiries like Lynparza.
Approval Date: July 27, 2026Product Dosage: 100mg/5mLTTM Revenue: Rs 1933 CrFY24 Tagrisso Sales: Rs 319.9 Cr
📅 Short termThe news is likely to be viewed positively by the market as it strengthens the company's specialty portfolio in the high-margin oncology space.
📈 Long termContinuous expansion of drug indications is essential for justifying the company's high P/E multiple (175.4) and supporting its transition to an import-based specialist model.
⚠ Risk flags
- High dependency on parent entities for product supply
- Pricing and access challenges in the Indian market
- Competition from other HER2-targeted therapies
Key Highlights
Received CDSCO permission on July 27, 2026, for import and sale of Enhertu® for a new indication.
Indicated for neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer.
The approval covers Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion.
Supports the parent company's global target of reaching USD 80 billion in revenue by 2030.
👀 What to Watch
Investors should monitor the commercial launch timeline for this indication and its contribution to the Oncology segment's growth in future quarterly earnings.
CFO Bhavana Agrawal to Resign Effective August 31, 2026, for Regional Role
AstraZeneca Pharma India Limited has announced that Ms. Bhavana Agrawal, Executive Director and CFO, will resign effective August 31, 2026. The resignation is not a departure from the group but a transition to a regional role within the AstraZeneca Group. This change occurs as the company manages a TTM revenue of ₹1,933 Cr and a high P/E valuation of 175.0. The company will need to appoint a successor to oversee its strategic shift toward an import-based specialist model and its exit from the Bangalore manufacturing site.
Confidence: HIGH
What changedThe Chief Financial Officer is stepping down from the Indian entity to take up a regional position within the parent AstraZeneca Group.
Why it mattersAs a Key Managerial Personnel (KMP), the CFO plays a critical role in managing the financial health and regulatory compliance of a company valued at over ₹20,000 Cr, especially during its exit from local manufacturing.
Effective Date of Cessation: August 31, 2026CFO Shareholding: NILTTM Revenue: ₹1,933 CrMarket Cap: ₹20,138 Cr
📅 Short termThe stock is likely to remain neutral as the departure is an internal group transition rather than a resignation due to performance or governance issues.
📈 Long termLimited structural impact expected, provided the company maintains its innovation pipeline and successfully manages the transition to an import-heavy product mix.
⚠ Risk flags
- Succession risk if a new CFO is not appointed in a timely manner
Key Highlights
CFO Ms. Bhavana Agrawal to resign effective close of business hours on August 31, 2026
Transition is due to an appointment to a regional role within the global AstraZeneca Group
Outgoing CFO holds NIL shares in the company as per the filing
Company reported TTM revenue of ₹1,933 Cr and TTM PAT of ₹115 Cr
AstraZeneca India is currently trading at a P/E of 175.0 with a market cap of ₹20,138 Cr
👀 What to Watch
Monitor the announcement of the successor CFO to ensure continuity in the company's strategic transition toward an import-based model and its 'Growth through Innovation' strategy.
Rs 36 Dividend Proposed; 47th AGM Scheduled for August 10, 2026
AstraZeneca Pharma India has issued a notice for its 47th Annual General Meeting (AGM) to be held on August 10, 2026. The board has proposed a dividend of Rs 36 per share for FY 2025-26, which represents a high payout ratio of approximately 78% against the TTM EPS of Rs 46.02. Other key agenda items include the appointment of BSR & Co. LLP as statutory auditors for a five-year term and the re-appointment of Ms. Shilpa Divekar Nirula as an Independent Director. The company continues its strategic shift toward an import-based specialist model while exiting its Bangalore manufacturing site.
Confidence: HIGH
What changedThe company has formalized the schedule for its annual shareholder meeting and confirmed the proposed dividend amount for the previous fiscal year.
Why it mattersThe AGM is the primary forum for shareholders to approve the dividend payout and confirm the appointment of auditors and directors, ensuring governance continuity for the next five years.
Proposed Dividend: Rs 36 per shareDividend Payout Ratio (vs TTM EPS): 78.2%Auditor Appointment Term: 5 yearsAGM Date: August 10, 2026TTM Revenue: Rs 1933 Cr
📅 Short termThe stock may see minor interest leading up to the AGM and the subsequent record date for the Rs 36 dividend.
📈 Long termLimited structural impact from this routine filing; long-term performance depends on the success of new product launches and the strategic alliance with Sun Pharma.
⚠ Risk flags
- High dependency on parent entities for product supply
- Revenue impact from patent expiry of key drugs like Lynparza
- Gross margin pressure due to shift to trading-heavy mix
Key Highlights
Proposed dividend of Rs 36 per equity share for the financial year 2025-26.
47th Annual General Meeting scheduled for August 10, 2026, at 3:00 PM IST via video conferencing.
Proposed appointment of M/s. BSR & Co. LLP as Statutory Auditors for a 5-year term until the 2031 AGM.
Re-appointment of Ms. Shilpa Divekar Nirula as Independent Director for a second 5-year term starting December 29, 2026.
TTM Revenue stands at Rs 1,933 Cr with a current P/E ratio of 174.3.
👀 What to Watch
Investors should monitor the AGM voting results for the approval of the dividend and auditor appointments. The high dividend payout is notable, but the primary focus remains on the company's transition to a trading-heavy product mix and the impact of patent expiries.
CDSCO Approval for Fasenra® (Benralizumab) for Hypereosinophilic Syndrome (HES)
AstraZeneca Pharma India received CDSCO approval on July 15, 2026, to import and distribute Benralizumab (Fasenra®) for a new indication: Hypereosinophilic Syndrome (HES) in patients aged 12 and older. This approval expands the addressable market for Fasenra, a key product in the company's specialty portfolio. The move aligns with the company's strategy of 'Growth through Innovation,' following 9 regulatory approvals achieved in FY24. As the company exits its Bangalore manufacturing site, its reliance on such import-based approvals for high-value innovative medicines becomes central to its TTM revenue of ₹1,933 Cr.
Confidence: HIGH
What changedAstraZeneca India has gained regulatory clearance to market its existing drug Fasenra for an additional medical condition (HES), expanding its clinical utility in India.
Why it mattersThis is part of the company's strategy to offset revenue losses from patent expiries (like Lynparza) by introducing new indications and innovative products from its global parent's pipeline.
Approval Date: July 15, 2026Dosage Strength: 30 mg/mlTarget Patient Age: 12 years and olderTTM Revenue: ₹1,933 CrFY24 Approvals: 9
📅 Short termThe news is likely to be viewed positively by the market as it demonstrates a continuous pipeline of regulatory milestones, though immediate revenue impact will be incremental.
📈 Long termStructural shift towards high-margin, innovative imported drugs is key to sustaining ROCE (currently 29%) as the company moves away from a manufacturing-heavy model.
⚠ Risk flags
- High dependency on parent entities for product supply
- Niche market size for Hypereosinophilic Syndrome
- Gross margin pressure from trading-heavy product mix
Key Highlights
Received CDSCO permission on July 15, 2026, for import and sale of Benralizumab 30 mg/ml.
New indication targets patients aged 12 years and older with Hypereosinophilic Syndrome (HES).
The product will be marketed under the brand name Fasenra® in pre-filled syringe format.
Follows a successful FY24 where the company secured 9 regulatory approvals for various medicines.
Supports the strategic shift toward an import-based specialist model for chronic and rare diseases.
👀 What to Watch
Investors should monitor the commercial launch timeline for this indication and track the overall volume growth in the specialty segment, particularly as the company transitions away from local manufacturing.
AstraZeneca India Appoints 3 New Directors for Oncology, Rare Diseases, and Strategy
AstraZeneca Pharma India has announced three key leadership appointments to its Senior Management Personnel (SMP) effective August and September 2026. Mr. Mihir Parikh and Mr. Amay Ashok Pandey join as Directors for Commercial Excellence/Strategy and Oncology respectively, while Mr. Vinay Sharma is promoted to Director of Rare Diseases. These roles are critical as the company focuses on high-growth specialty segments like Oncology, where Tagrisso alone contributed ₹319.9 Cr in sales. The appointments align with the company's strategy to bring innovative medicines to India following 9 regulatory approvals in FY24.
Confidence: HIGH
What changedThe company has filled three senior management positions to lead its core business units and strategic growth initiatives.
Why it mattersThese leaders will be responsible for executing the company's 'Growth through Innovation' strategy and managing the transition to a trading-heavy product mix, which currently impacts gross margins.
Tagrisso Sales (FY24): ₹319.9 CrRegulatory Approvals (FY24): 9TTM Revenue: ₹1,933 CrMihir Parikh Experience: 15+ yearsAmay Ashok Pandey Experience: 18+ years
📅 Short termThe announcement is procedural and unlikely to impact the stock price in the immediate term.
📈 Long termThe success of these leaders in navigating patent expiries (like Lynparza) and launching new assets will be structural to the company's long-term profitability.
⚠ Risk flags
- Execution risk in high-competition oncology markets
- High dependency on parent entity for product supply
Key Highlights
Mr. Mihir Parikh appointed Director - Commercial Excellence, BD & Strategy effective August 1, 2026
Mr. Amay Ashok Pandey appointed Director - Oncology Business Unit effective September 1, 2026
Mr. Vinay Sharma promoted to Director - Rare Diseases Business Unit effective August 1, 2026
Oncology is a major revenue driver with Tagrisso sales reaching ₹319.9 Cr in FY24
The company is transitioning to an import-based specialist model after exiting its Bangalore manufacturing site
👀 What to Watch
Investors should monitor the pace of new product launches and market share gains in the Oncology and Rare Disease segments under this new leadership team.
AstraZeneca Pharma India Announces Resignation of Two Senior Management Personnels
AstraZeneca Pharma India Limited has announced the resignation of two key senior management officials. Ms. Aditi Mehta, Business Unit Director for the Oncology Business Unit, and Mr. Srikanth B.S., Site Lead for India Operations, are leaving to pursue opportunities outside the company. Ms. Mehta's resignation is effective June 12, 2026, while Mr. Srikanth will depart on June 15, 2026. The company is currently searching for a suitable replacement for the Oncology leadership position.
Key Highlights
Ms. Aditi Mehta, Business Unit Director – Oncology, resigned effective June 12, 2026.
Mr. Srikanth B.S., Site Lead – India Operations, resigned effective June 15, 2026.
Both departures are attributed to the individuals pursuing career opportunities outside the organization.
The company has initiated a search for a replacement for the Oncology Business Unit Director role.
👀 What to Watch
Investors should monitor the company's ability to fill these senior roles promptly, particularly the Oncology lead, to ensure business continuity in key segments.
AstraZeneca India Gets CDSCO Approval for Enhertu for Additional Breast Cancer Indication
AstraZeneca Pharma India has received approval from the CDSCO to import and market Enhertu (Trastuzumab deruxtecan 100 mg/5mL) for an additional indication in India. The drug is now approved for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer when used in combination with pertuzumab. This regulatory milestone expands the therapeutic reach of one of the company's key oncology products, potentially driving long-term revenue growth in the specialty medicines segment.
Key Highlights
Received CDSCO permission on June 10, 2026, for import and sale of Enhertu (Trastuzumab deruxtecan 100 mg/5mL).
Approval granted for first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+ or ISH+) breast cancer.
The treatment is indicated for use in combination with pertuzumab, expanding the drug's clinical application.
Marketing for the new indication is subject to any remaining statutory approvals.
👀 What to Watch
Investors should monitor the commercial uptake of Enhertu for this new indication as it strengthens the company's oncology portfolio. The expansion into first-line treatment significantly increases the eligible patient pool compared to later-line therapies.
AstraZeneca India FY26 Revenue Up 33% to ₹2,276 Cr; Recommends ₹36 Dividend
AstraZeneca Pharma India reported a robust 33% YoY revenue growth, reaching INR 22,755.8 million for FY 2025-26. The growth was primarily driven by the Oncology segment, which contributed INR 16,100.9 million, followed by Biopharmaceuticals at INR 5,243.2 million. The company achieved 11 regulatory approvals for new medicines and indications during the year, significantly strengthening its product pipeline. Additionally, the Board recommended a substantial dividend of INR 36 per share, reflecting strong cash flow and commitment to shareholder returns.
Key Highlights
Total Revenue from operations grew 33% YoY to INR 22,755.8 million for FY 2025-26.
Oncology segment remains the largest contributor with revenue of INR 16,100.9 million.
Recommended a final dividend of INR 36 per equity share of face value INR 2.
Secured 11 regulatory approvals from CDSCO for various indications including Oncology and Rare Diseases.
Full-year Profit After Tax (PAT) reached INR 1,875.2 million with an unmodified audit opinion.
👀 What to Watch
Investors should take note of the strong 33% top-line growth and the aggressive pipeline expansion through 11 new approvals. The high dividend payout of 1800% on face value makes it an attractive pick for growth and income-focused portfolios.
AstraZeneca India FY26 Revenue Grows 33% to INR 22,756 Mn; 11 New Regulatory Approvals
AstraZeneca Pharma India reported a robust 33% year-on-year growth in total revenue for FY 2025-26, reaching INR 22,755.8 million. The growth was primarily driven by the Oncology segment, which contributed INR 16,100.9 million, followed by Biopharmaceuticals at INR 5,243.2 million. The company secured 11 new regulatory approvals for various medicines and indications, significantly strengthening its future product pipeline. Profit after tax for the full year stood at INR 1,875.2 million, reflecting strong operational execution and portfolio expansion.
Key Highlights
Total revenue for FY 2025-26 reached INR 22,755.8 million, marking a consistent 33% year-on-year growth.
Oncology segment dominated performance with INR 16,100.9 million in revenue, while Rare Disease contributed INR 214.6 million.
Secured 11 regulatory approvals from CDSCO for new medicines and indications, including Durvalumab and Osimertinib.
Full-year Profit After Tax (PAT) reached INR 1,875.2 million with Q4 PAT at INR 448.8 million.
Launched Eculizumab, the first anti-complement therapy approved in India for specific rare diseases.
👀 What to Watch
Investors should focus on the company's aggressive pipeline expansion and dominant position in the high-margin Oncology segment. The 11 new approvals provide high revenue visibility for the next 2-3 years.
AstraZeneca India Gets CDSCO Approval for Calquence® in Untreated Mantle Cell Lymphoma
AstraZeneca Pharma India has received approval from the CDSCO to import and market Acalabrutinib maleate tablets 100 mg (Calquence®) for an additional indication. The drug is now approved for use in combination with Bendamustine and Rituximab for treating adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for stem cell transplants. This regulatory milestone expands the company's oncology portfolio in India, following the receipt of permission on May 20, 2026. The approval paves the way for the commercial distribution of this therapy in the Indian market.
Key Highlights
Received CDSCO permission to import and distribute Acalabrutinib maleate 100 mg (Calquence®) for a new indication.
Approval covers treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
The therapy is indicated for patients ineligible for autologous stem cell transplant (ASCT) in combination with BR.
Permission was granted by the Directorate General of Health Services on May 20, 2026.
👀 What to Watch
Investors should monitor the commercial launch and market penetration of Calquence® for this new indication as it strengthens the company's high-margin oncology segment. This expansion is likely to contribute positively to long-term revenue growth in the specialty medicine category.
AstraZeneca India Receives CDSCO Approval for Calquence (Acalabrutinib) Additional Indication
AstraZeneca Pharma India has received regulatory approval from the CDSCO to import and market Acalabrutinib 100 mg tablets (Calquence) for an additional indication. The drug is now authorized for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) when used in combination with venetoclax. This approval expands the company's oncology portfolio in India, targeting a broader patient base. The commercial launch for this indication remains subject to any further statutory approvals.
Key Highlights
Received CDSCO permission on April 9, 2026, for Acalabrutinib 100 mg tablets (Calquence).
New indication covers previously untreated chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
Approval includes combination therapy with venetoclax, with or without obinutuzumab.
Expands AstraZeneca's therapeutic footprint in the high-growth oncology segment in India.
👀 What to Watch
Investors should monitor the commercial uptake of Calquence for this new indication as it strengthens the company's specialized medicine portfolio. This regulatory milestone is a positive driver for long-term revenue growth in the oncology division.
AstraZeneca India Appoints New Medical Director (Oncology) and Market Access Director
AstraZeneca Pharma India has announced two key leadership appointments effective April 1, 2026, to strengthen its Oncology and Market Access divisions. Dr. Shashank Srinivasan, a clinical oncologist and former Pfizer lead, has been appointed as Medical Director for the Oncology Business Unit. Additionally, Mr. Venkat Natarajan, who has approximately 20 years of industry experience, has been promoted to Director of the Market Access Business Unit. These strategic appointments are aimed at enhancing the company's precision care delivery and patient affordability programs in India.
Key Highlights
Dr. Shashank Srinivasan appointed as Medical Director – Oncology Business Unit effective April 1, 2026.
Mr. Venkat Natarajan promoted to Director – Market Access Business Unit effective April 1, 2026.
Mr. Natarajan brings nearly 20 years of experience from major firms including Pfizer, Novartis, and MSD.
Dr. Srinivasan is an alumnus of Tata Memorial Hospital with specialized expertise in GI and Lung cancers.
The appointments focus on strengthening the company's oncology portfolio and state-level insurance access models.
👀 What to Watch
These leadership changes reinforce AstraZeneca's focus on the high-growth oncology segment and market penetration. Investors should watch for improved execution in product launches and expanded market access under the new leadership.
AstraZeneca Pharma India Shareholders Approve Material Related Party Transactions
AstraZeneca Pharma India Limited has announced that its shareholders have approved ordinary resolutions regarding material transactions with related parties via a postal ballot. The voting results, declared on March 31, 2026, confirm that the resolutions were passed by non-related members with the requisite majority. This approval is a mandatory regulatory requirement under SEBI (LODR) Regulations for significant business dealings with group entities. The successful vote ensures the company remains compliant while executing its operational strategy involving parent or sister concerns.
Key Highlights
Ordinary resolutions for Material Related Party Transactions passed with requisite majority.
Voting results finalized on March 31, 2026, following a Postal Ballot notice dated February 11, 2026.
Approval obtained specifically from non-related members to ensure fair corporate governance.
Compliance maintained under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 What to Watch
No immediate action is required as this is a routine regulatory approval for business operations. Investors should monitor future financial statements to understand the scale and impact of these related party transactions on margins.
AstraZeneca India Receives CDSCO Approval for Imfinzi to Treat Liver Cancer (uHCC)
AstraZeneca Pharma India has received approval from the CDSCO to import and market Durvalumab (Imfinzi) for an additional indication in India. The drug is now indicated for treating unresectable hepatocellular carcinoma (uHCC) in patients who have not received prior systemic therapy. This approval covers two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL. This expansion into liver cancer treatment strengthens the company's oncology portfolio and opens a new revenue stream in the Indian market.
Key Highlights
Received CDSCO permission for import and distribution of Durvalumab (Imfinzi) for a new indication
Indicated for unresectable hepatocellular carcinoma (uHCC) in treatment-naive patients
Approval covers two formulations: 120 mg/2.4 mL and 500 mg/10 mL solution for infusion
Expands AstraZeneca's oncology portfolio and addressable market in India
👀 What to Watch
Investors should view this as a positive development for long-term growth in the oncology segment. Monitor the commercial rollout and its impact on the company's specialty care revenue in upcoming quarters.
AstraZeneca Pharma India Seeks Approval for ₹3,900 Cr Related Party Transactions
AstraZeneca Pharma India Limited has issued a postal ballot notice to seek shareholder approval for material related party transactions (RPT) for the 2026-27 fiscal year. The company proposes transactions worth up to ₹2,400 crore with AstraZeneca UK Limited and up to ₹1,500 crore with AstraZeneca AB, Sweden. These transactions cover the purchase, transfer, or receipt of products, goods, and services essential for operations. The e-voting period is scheduled from February 28 to March 29, 2026, with results expected by March 31, 2026.
Key Highlights
Proposed transactions with AstraZeneca UK Limited capped at ₹2,400 crore for FY 2026-27.
Proposed transactions with AstraZeneca AB, Sweden capped at ₹1,500 crore for FY 2026-27.
Total value of material related party transactions under consideration is ₹3,900 crore.
E-voting period runs from February 28, 2026, to March 29, 2026.
Transactions include purchase of products, goods, materials, and reimbursement of transfer price or other obligations.
👀 What to Watch
Investors should monitor the voting results and review the explanatory statement to ensure these large-scale transactions with parent entities are conducted at arm's length.
